Brokerages Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Price Target at $33.33

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $33.3333.

Several research firms have commented on GLUE. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Zacks Research lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday. JPMorgan Chase & Co. increased their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Guggenheim boosted their price objective on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, Wells Fargo & Company decreased their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th.

Monte Rosa Therapeutics Stock Up 1.9%

GLUE opened at $24.52 on Friday. Monte Rosa Therapeutics has a 12-month low of $4.12 and a 12-month high of $25.77. The business has a 50 day moving average of $19.73 and a 200-day moving average of $19.11. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -16.57 and a beta of 1.56.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. As a group, analysts expect that Monte Rosa Therapeutics will post -1.23 earnings per share for the current year.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, COO Jennifer Champoux sold 2,176 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total value of $41,344.00. Following the transaction, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at $1,185,049. This represents a 3.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director directly owned 10,000 shares of the company’s stock, valued at $231,100. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 81,778 shares of company stock valued at $1,768,581. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $30,000. Nisa Investment Advisors LLC grew its position in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after acquiring an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after acquiring an additional 776 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Monte Rosa Therapeutics in the fourth quarter worth about $63,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Monte Rosa Therapeutics in the 3rd quarter valued at approximately $32,000. 79.96% of the stock is currently owned by institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.